Introduction
============

Sexually transmitted infections (STI) are important health risks for people living with HIV infection in the era of combination antiretroviral therapy (cART) ([@ref-12]). Surveillance reports of syphilis, gonorrhoea and chlamydia have risen during the 2000s, particularly in men who have sex with men (MSM) ([@ref-6]; [@ref-8]). In addition, there have been outbreaks of STI which were previously rare, like lymphogranuloma venereum (LGV) ([@ref-5]; [@ref-3]; [@ref-28]) and hepatitis C ([@ref-27]; [@ref-30]) in HIV positive MSM.

Regular testing for STI is recommended in some countries as part of routine follow up for all people with HIV infection ([@ref-7]; [@ref-12]). But the levels of STI at which regular testing in people with HIV infection is worthwhile are unclear ([@ref-20]). Estimating the frequency of STI can be difficult because cohort studies are challenging ([@ref-14]; [@ref-20]) and cross-sectional studies miss episodes diagnosed in different settings at different times. [@ref-13] tried to overcome this challenge by combining diagnoses made at yearly study visits with self-reported diagnoses in the past year in a cohort of HIV negative MSM.

There are no guidelines for regular STI testing in HIV-infected people in Switzerland. [@ref-24] (SHCS) ([@ref-24]) provides regular follow up and care for about 7500 people with HIV infection in Switzerland, of whom 30% are women and 35% are assumed to have acquired HIV through sex between men. The aim of this study was to inform decisions about the need for regular STI screening in HIV-infected people in Switzerland. Specific objectives were to estimate the prevalence of bacterial and viral STI and patterns of sexual health care seeking behaviour in sexually active HIV-infected MSM, heterosexual men and women.

Methods
=======

We enrolled patients attending routine visits to the outpatient HIV clinic of the Bern University Hospital, Switzerland from 20.05.2009 to 28.05.2010 when a clinic physician was available to explain the study. Patients were eligible for inclusion if they were aged 18 years or older, had confirmed HIV infection, were enrolled in the SHCS, had had sexual intercourse in the last 12 months and gave written consent. The doctor administered a standardised questionnaire (in German, French or English) that asked about recent sexual partner history, previous STI and case management. All patients underwent a standard physical examination and gave a first-catch urine specimen and a blood sample. Additional specimens were taken from the throat and/or rectum from patients who reported having had receptive oral or anal sex in the last year. Whilst waiting for their blood test, patients were asked to complete a supplementary questionnaire, which they posted into a box in the clinic or returned later by mail. There were additional questions about satisfaction with management for previous STI and preferences for future sexual health services. All questionnaires were labelled with only a unique identification number to protect confidentiality. Additional epidemiological, patient history and cART data were derived from the SHCS database. The Canton of Bern Ethical Committee approved the study protocol (application number 026/09).

Specimens were tested in the laboratory of the University Institute of Infectious Diseases, according to manufacturers' instructions. First catch urine specimens were tested by polymerase chain reaction for *Chlamydia trachomatis* (COBAS TaqMan CT Test v2.0, Roche Diagnostics, Rotkreuz, Switzerland) and *Neisseria gonorrhoeae* (*opa*-based real-time PCR assay, TIB Molbiol, Berlin, Germany, on the COBAS TaqMan Analyzer, Roche Diagnostics); tests that were positive for *C. trachomatis* were further examined and typed for LGV strains (*omp*A-based in-house assay, Institute for Medical & Molecular Diagnostics, Zürich, Switzerland). Blood was tested for herpes simplex type 2 (HSV-2) antibodies (HerpeSelect 2 ELISA IgG, Focus Diagnostics, Cypress, CA, USA). Results of the most recent serological tests for syphilis, hepatitis B and hepatitis C infections were obtained from the patient's SHCS clinical record.

Patients with a diagnosed STI received their results by telephone from the treating physician and received antibiotic treatment, where appropriate, from the clinic. Uncomplicated chlamydia was treated with azithromycin 1 g as a single dose or doxycycline 100 mg twice daily for seven days, LGV doxycycline 100 mg twice daily for 21 days. Gonorrhoea was treated with ceftriaxone 250 mg by intramuscular injection. Partner management was discussed at the same visit and partners were contacted by the study doctor, with the agreement of the patient. Outcomes of partner notification were asked at the next follow up visit.

Statistical analysis
--------------------

Our study plan assumed that 700 HIV-infected patients would visit the outpatient clinic in one year and 50% would be enrolled. Based on published studies, if the prevalence of chlamydia or gonorrhoea was 10% (35/350), 95% confidence intervals (95% CI) would be 7.0% to 13.6% ([@ref-18]; [@ref-14]; [@ref-10]).

We conducted descriptive univariable analyses separately amongst MSM, heterosexual men and women and made statistical comparisons between groups using chi-squared tests. In all analyses heterosexual women and women who have sex with women were considered as a single group because of the small number; no woman who has sex with women was diagnosed with an STI. In each group we estimated the point prevalence of STI (with 95% CI) amongst sexually active HIV-positive people tested using the number with a positive test result at the study visit as a percentage of all participants. We used the method of [@ref-13] to estimate a one-year rate of diagnosed bacterial STI by adding study-diagnosed infections and self-reported infections in the previous year. We did not do multivariable analyses because the study was not designed to investigate risk factors for STI.

Results
=======

We enrolled 232 HIV-infected patients during the study period. Study clinicians assessed 698 patients for eligibility ([Fig. 1](#fig-1){ref-type="fig"}). Of these, 250 (36%) did not fulfil the inclusion criteria and 216 (31%) declined to participate. Amongst the enrolled patients (232/448, 52% of those eligible), eight were excluded from analysis because their records could not be linked to an SHCS number. Amongst the 224 included study participants there were 177 men (112 men who have sex with men and 65 heterosexual men) and 47 women (44 heterosexual and 3 women who have sex with women).

![Flow chart of included and excluded patients.](peerj-02-537-g001){#fig-1}

Characteristics, STI Risks and symptoms amongst participants
------------------------------------------------------------

[Table 1](#table-1){ref-type="table"} shows the social and demographic characteristics of study participants. Their mean age was 44 years (standard deviation, SD 9.1 years), almost all had received antiretroviral therapy and most had an undetectable viral load on the day of the study visit. Compared with all patients under active follow up in Bern ([@ref-24]) patients in this study were less likely to be female (20% vs. 35%).
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###### Characteristics of study participants at enrolment (*N* = 224).

![](peerj-02-537-g002)

  Characteristic                                                                                                 *N*   (%)
  ----------------------------------------------------------------- -------------------------------------------- ----- --------
  Sex, sexual orientation                                           Men who have sex with men                    112   (50.0)
                                                                    Heterosexual men                             65    (29.1)
                                                                    Heterosexual women                           44    (19.6)
                                                                    Women who have sex with women                3     (1.3)
  Route of HIV acquisition                                          Sex between men                              108   (48.2)
                                                                    Heterosexual sex                             77    (34.4)
                                                                    Injection drug use                           26    (11.6)
                                                                    Other or unknown                             13    (5.8)
  Country of birth                                                  Switzerland                                  113   (50.4)
                                                                    Other                                        35    (15.6)
                                                                    Missing                                      76    (33.9)
  Age in years, mean (standard deviation)                           44.4 (9.1)                                   na    
  CD4 count on day of visit, cells/µ l, mean (standard deviation)   525.9 (280)                                  na    
  Viral load \<40 copies/mL                                         Yes, received antiretroviral therapy         154   (68.8)
                                                                    Yes, never received antiretroviral therapy   2     (0.9)
                                                                    No, ever received antiretroviral therapy     16    (7.1)
                                                                    No, never received antiretroviral therapy    37    (16.5)
                                                                    Missing                                      15    (6.7)

**Notes.**

nanot applicableMSMmen who have sex with menSTIsexually transmitted infection

Reported sexual behaviours differed by sex and sexual orientation ([Table 2](#table-2){ref-type="table"}). Almost 70% of MSM reported two or more sexual partners in the last 12 months compared with 21.5% of heterosexual men and 10.7% of women (*p* \< 0.001). MSM were more likely than heterosexual men or women to report having casual sexual partners alone or both casual and regular partners (*p* \< 0.001). Amongst participants reporting any casual partners, ≥50% reported consistent condom use, including three quarters of MSM who reported receptive anal sex. Consistent condom use for receptive anal sex was also reported by almost three quarters of MSM reporting any regular partners. For vaginal sex, most heterosexual men, but not women, reported consistent condom use.
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###### Sexual behaviours reported by patient to physician (*N* = 224).
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                 MSM           Heterosexual men   Women        *P* value                          
  ------------------------------------------------------------------------------ ------------- ------------------ ------------ ----------- ------------ --------- ---------
  **Symptoms and sexual partnerships**                                           **N = 112**   **(%)**            **N = 65**   **(%)**     **N = 47**   **(%)**   

  Any STI symptoms on day of visit                                                                                                                                

  Yes                                                                            7             (6.4)              3            (4.6)       1            (2.1)     0.562

  No                                                                             102           (91.1)             62           (95.4)      45           (97.8)    

  Not reported                                                                   3             (2.7)              0            \(0\)       1            (2.1)     

  Total number of sexual partners\                                                                                                                                
  in past year                                                                                                                                                    

  1                                                                              34            (30.4)             51           (78.5)      42           (89.4)    \<0.001

  2--4                                                                           23            (20.5)             11           (16.9)      3            (6.4)     

  5                                                                              55            (49.1)             3            (4.6)       2            (4.3)     

  **Sexual partnership type(s)**                                                                                                                                  

  Casual partners only                                                           44            (39.3)             14           (21.5)      2            (4.3)     \<0.001

  Both regular and casual partners                                               34            (30.4)             3            (4.6)       4            (8.5)     

  Regular partners only                                                          34            (30.4)             48           (73.8)      41           (87.2)    

  **Sexual practices, any casual partners** [^a^](#table-2fn2){ref-type="fn"}    **N = 78**    **(%)**            **N = 17**   **(%)**     **N = 6**    **(%)**   

  Receptive anal intercourse                                                                                                                                      

  Yes, consistent condom use                                                     46            (59.0)             0            \(0\)       3            (50.0)    \<0.001

  Yes, no consistent condom use                                                  14            (18.0)             0            \(0\)       0            \(0\)     

  No or not reported                                                             18            (23.0)             17           \(100\)     3            (50.0)    

  Insertive anal intercourse                                                                                                                                      

  Yes, consistent condom use                                                     37            (47.4)             1            (5.9)       0            \(0\)     \<0.001

  Yes, no consistent condom use                                                  17            (21.8)             1            (5.9)       0            \(0\)     

  No or not reported                                                             24            (30.8)             15           (88.2)      6            \(100\)   

  Vaginal intercourse                                                                                                                                             

  Yes, consistent condom use                                                     4             (5.1)              14           (82.4)      2            (33.3)    \<0.001

  Yes, no consistent condom use                                                  0             \(0\)              2            (11.8)      1            16.7)     

  No or not reported                                                             74            (94.9)             1            (5.9)       3            (50.0)    

  **Sexual practices, any regular partners** [^b^](#table-2fn3){ref-type="fn"}   **N = 68**    **(%)**            **N = 51**   **(%)**     **N = 45**   **(%)**   

  Receptive anal intercourse                                                                                                                                      

  Yes, consistent condom use                                                     37            (54.4)             0            \(0\)       1            (2.2)     \<0.001

  Yes, no consistent condom use                                                  14            (20.6)             0            \(0\)       0            \(0\)     

  No or not reported                                                             17            (25.0)             51           \(100\)     44           (97.8)    

  Insertive anal intercourse                                                                                                                                      

  Yes, consistent condom use                                                     31            (45.6)             0            \(0\)       0            \(0\)     \<0.001

  Yes, no consistent condom use                                                  8             (11.8)             1            (2.0)       0            \(0\)     

  No or not reported                                                             29            (42.7)             50           (98.0)      45           \(100\)   

  Vaginal intercourse                                                                                                                                             

  Yes, consistent condom use                                                     3             (4.4)              36           (70.6)      24           (53.3)    \<0.001

  Yes, no consistent condom use                                                  1             (1.5)              14           (27.5)      17           (37.8)    

  No or not reported                                                             64            (94.1)             1            (1.9)       4            (8.9)     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes.**

MSMmen who have sex with menSTIsexually transmitted infection

Number with any casual partners is sum of those with only casual and those with both casual and regular partners.

Number with any regular partners is sum of those with only regular and those with both casual and regular partners.

Diagnosed sexually transmitted and sexually transmissible infections
--------------------------------------------------------------------

Few participants (11/224, 4.9%) reported any symptoms associated with STI on the day of study enrolment (see [Table 2](#table-2){ref-type="table"}).

Bacterial infections
--------------------

Sixteen men had positive test results for *N. gonorrhoeae*, *C. trachomatis*, or both at the study visit. The prevalence of each STI (% and 95% CI) on the day of study enrolment is shown in [Table 3](#table-3){ref-type="table"}. Three MSM (2.7%, 95% CI 0.9, 8.0%) had gonococcal infection (two rectal, one pharyngeal). One heterosexual man had pharyngeal gonorrhoea; he did not report any male sexual partners and there was no confirmatory specimen for culture before treatment. All 13 chlamydia-infected participants were MSM; 12 (10.7%, 95% CI 6.2, 18.0%) had *C. trachomatis* serovars D-K detected (five urethral, six rectal, one pharyngeal) and one had a rectal LGV serovar 2b. One MSM had both rectal gonorrhoea and chlamydia. There were 45 participants with positive serologic tests for syphilis with the highest estimated prevalence amongst MSM (*p* \< 0.001). Amongst MSM, six (5.4%, 95% CI 2.9, 11.3%) had newly reactive serological tests for syphilis during the study period.
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###### Laboratory diagnosed sexually transmitted infections (*n* = 224).

Numbers in italics show the distribution of infections by site.

![](peerj-02-537-g004)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Infection                                                         MSM,\         Heterosexual men,\   Women,\      *P* value                                     
                                                                    *N* = *112*   *N* = *65*           *N* = *47*                                                 
  ----------------------------------------------------------------- ------------- -------------------- ------------ ------------------- ----- ------------------- ---------
  Chlamydia, serovars D-K                                           12            10.7 (6.2, 18.0)     0            --                  0     --                  0.002

  *Urethral*                                                        *5*                                *0*                              *0*                       

  *Rectal*                                                          *6*                                *0*                              *0*                       

  *Pharyngeal*                                                      *1*                                *0*                              *0*                       

  LGV, rectal                                                       1             0.9 (0.1, 6.2)       0            --                  0     --                  0.606

  Gonorrhoea                                                        3             2.7 (0.9, 8.0)       1            1.5 (0.2, 10.3)     0     --                  0.499

  *Urethral*                                                        *0*                                *0*                              *0*                       

  *Rectal*                                                          *2*                                *0*                              *0*                       

  *Pharyngeal*                                                      *1*                                *1*                              *0*                       

  Syphilis[^b^](#table-3fn2){ref-type="fn"}                                                                                                                       

  Any positive serologic test                                       39            34.8 (26.5, 44.2)    1            1.5 (0.2, 10.3)     5     10.6 (4.5, 23.3)    \<0.001

  Seroconversion during study period                                6             5.4 (2.0, 11.3)      0            --                  0     --                  0.046

  HSV-2                                                             58            51.8 (39.1, 57.5)    23           35.4 (24.7, 47.8)   28    59.6 (45.0, 72.6)   0.028

  Hepatitis C, antibody positive[^c^](#table-3fn3){ref-type="fn"}   7             6.3 (3.0, 12.6)      21           32.3 (22.0, 44.6)   10    21.3 (11.8, 35.3)   \<0.001

  Hepatitis B[^d^](#table-3fn4){ref-type="fn"}                                                                                                                    0.117

  sAg or eAg positive                                               2             1.8 (0.4, 6.9)       6            9.2 (4.2, 19.2)     2     4.3 (1.1, 15.6)     

  Core antibody positive                                            46            41.1 (32.3, 50.5)    19           29.2 (19.4, 41.5)   21    44.7 (31.2, 59.1)   

  Surface antibody positive,\                                       27            24.1 (17.0, 33.0)    15           23.1 (14.4, 34.9)   13    27.7 (16.7, 42.1)   
  core antibody negative                                                                                                                                          

  Non-immune                                                        28            25.0 (17.8, 33.9)    23           35.4 (24.7, 47.8)   10    21.3 (11.8, 35.3)   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes.**

One MSM had both chlamydia and gonorrhoea.

Serologic tests done at baseline (Treponema pallidum haemagglutination assay, TPHA) and yearly thereafter, with follow up tests done as clinically indicated.

No result available for 11/112 MSM, 3/65 heterosexual men, 1/47 women.

No result available for 9/112 MSM, 2/65 heterosexual men, 1/47 women.

Viral infections
----------------

Viral infections were diagnosed serologically ([Table 3](#table-3){ref-type="table"}); no participant with HSV-2 antibodies reported genital ulceration on the day of the study visit. HSV-2 infection was common in all groups of participants with more than half of MSM and women, and a third of heterosexual men (*p* = 0.028), having antibodies detected. In contrast, antibodies to hepatitis C were more common in heterosexual men and in women than in MSM (*p* \< 0.001). Amongst patients with no recent history of injection drug use, more heterosexual men (7/46, 15.2%) and women (6/43, 14.0%) than MSM (4/109, 3.7%) had antibodies to hepatitis C (*p* = 0.038). Amongst those who acquired HIV through injection drug use, almost all had antibodies to hepatitis C (MSM, 3/3; heterosexual men 14/19; women 4/4, *p* = 0.523). Exposure to hepatitis B virus was common in all groups. A slightly higher percentage of heterosexual men (35.4%) than MSM (25.0%) or women (21.3%) were non-immune.

Cumulative diagnoses of acute sexually transmitted infections
-------------------------------------------------------------

Participants reported diagnoses, from a list of named STI, in the one year interval before the study. Overall, 19% (21/112) of MSM and 13% (6/47) of women reported having been diagnosed with any STI. [Table 4](#table-4){ref-type="table"} shows the one-year cumulative rate of bacterial STI, estimated as the sum of study diagnosed and self-reported (interval) infections as reported by [@ref-13]. The one-year cumulative rate of any chlamydial infection at any site was 16.1% (95% CI 10.3, 24.1%) in MSM and 4.3% (95% CI 1.1, 15.6%) in women and of gonorrhoea the rate was 4.5% (95% CI 1.9, 10.3%) in MSM and 1.5% (0.2, 10.3%) in heterosexual men. Additional self-reported interval STI included five MSM and one woman with genital warts, two MSM and three heterosexual men with genital herpes, one woman with pubic lice and one woman with scabies.
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###### Cumulative one year rate of laboratory confirmed and self-reported sexually transmitted infection diagnoses.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                            MSM, *N* = *1*12   Heterosexual men, *N* = *65*   Women, *N* = *4*7                                                   
  --------------------------------------------------------- ------------------ ------------------------------ ------------------- ----------------- --- ----------------- --- --- -----------------
  Chlamydia, any serovar[^b^](#table-4fn3){ref-type="fn"}   13                 5                              16.1 (10.3, 24.1)   0                 0   --                0   2   4.3 (1.1, 15.6)

  Gonorrhoea, any site                                      3                  2                              4.5 (1.9, 10.3)     1                 0   1.5 (0.2, 10.3)   0   0   --

  Syphilis[^c^](#table-4fn4){ref-type="fn"}                 6                  10                             14.3 (8.9, 22.1)    0                 0   --                0   1   2.1 (0.3, 13.8)

  Total number of\                                          31                 27.7 (21.1, 36.7)              1                   1.5 (0.2, 10.3)   3   6.4 (2.1, 21.0)           
  patients with\                                                                                                                                                                  
  any bacterial STI[^d^](#table-4fn5){ref-type="fn"}                                                                                                                              
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes.**

LGVlymphogranuloma venereumSTIsexually transmitted infection

Numbers of patients with infections diagnosed at study visit taken from [Table 3](#table-3){ref-type="table"}.

The question asked about chlamydia infection and did not distinguish between urogenital and LGV serovars or by clinical site of infection, so these have been grouped together.

Study diagnoses include only patients with serological evidence of new infection. Interval diagnoses include all those who said they had been diagnosed with syphilis in the previous year. Not asked if new or old diagnosis.

Total is the number of individual patients with either a study visit or interval diagnosis of any chlamydial infection, gonorrhoea or syphilis.

STI testing and healthcare seeking behaviour
--------------------------------------------

Amongst MSM and women, a substantial percentage reported that they had been tested for STI in the 12 months before the study visit (see [Table 5](#table-5){ref-type="table"}). Most patients who were tested reported that this had been done at an HIV outpatient clinic. The most common alternative source of STI care was private gynaecologists for women. A majority of participants in all groups reported that they felt comfortable speaking about sexual health and STI related issues with doctors in the HIV clinic. Opinions about the role of the STI clinic in offering regular STI testing differed between groups, however. About three quarters of MSM agreed that STI testing should be offered routinely every year. A sizeable minority of heterosexual men (10/48, 21%) and women (12/39, 31%) thought that STI tests should not be offered at HIV outpatient clinics.
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###### Previous sexually transmitted infection testing and management, reported by patients (*n* = 182).
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                MSM[^a^](#table-5fn2){ref-type="fn"}\   Heterosexual men,[^a^](#table-5fn2){ref-type="fn"}\   Women[^a^](#table-5fn2){ref-type="fn"},\   *P* value                 
                                                                *N* = 95                                *N* = 48                                              *N* = 39                                                             
  ------------------------------------------------------------- --------------------------------------- ----------------------------------------------------- ------------------------------------------ ----------- ---- -------- ---------
  Have you been tested for any STI in the last 12 months?                                                                                                                                                                          0.015

  Yes, tested positive for any STI                              21                                      (22.1)                                                4                                          (8.3)       6    (15.4)   

  Yes, tested negative for all                                  29                                      (30.5)                                                6                                          (12.5)      7    (18.0)   

  No, not tested                                                39                                      (41.1)                                                33                                         (68.8)      20   (51.3)   

  Not known                                                     6                                       (6.3)                                                 5                                          (10.4)      6    (15.4)   

  Where have tests for STI been done?                                                                                                                                                                                              0.006

  HIV outpatient clinic                                         45                                      (47.4)                                                8                                          (16.7)      9    (23.1)   

  STI specialist                                                0                                       \(0\)                                                 1                                          (2.1)       0    \(0\)    

  General practitioner                                          4                                       (4.2)                                                 1                                          (2.1)       0    \(0\)    

  Gynaecologist                                                 1                                       (1.1)                                                 0                                          \(0\)       4    (10.3)   

  Not tested or not known                                       45                                      (47.4)                                                38                                         (79.2)      26   (66.7)   

  Can you talk about sexual health and STI at the HIV clinic?                                                                                                                                                                      0.336

  Yes                                                           68                                      (71.6)                                                31                                         (64.6)      23   (59.0)   

  No                                                            23                                      (24.2)                                                15                                         (31.3)      14   (35.9)   

  No response                                                   4                                       (4.2)                                                 2                                          (4.2)       2    (5.1)    

  Should STI testing be done at the HIV outpatient clinic?                                                                                                                                                                         \<0.001

  Yes, regularly                                                69                                      (72.6)                                                17                                         (35.4)      16   (41.0)   

  Yes, but only if I have symptoms                              13                                      (13.7)                                                10                                         (20.8)      3    (7.7)    

  Yes, but only if I have been at risk                          5                                       (5.3)                                                 9                                          (18.8)      7    (18.0)   

  No                                                            6                                       (6.3)                                                 10                                         (20.8)      12   (30.8)   

  No response                                                   2                                       (2.1)                                                 2                                          (4.2)       1    (2.6)    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes.**

MSMmen who have sex with menSTIsexually transmitted infection

Not all participants returned a questionnaire; no responses from 17/112 MSM, 17/65 heterosexual men, 8/47 women.

Discussion
==========

Summary of main findings
------------------------

In this cross-sectional study of patients attending routine HIV outpatient clinics who reported having had sexual intercourse in the past year, the prevalence of laboratory diagnosed bacterial STI was higher in MSM than heterosexual men or women. The rate of bacterial STI in MSM and women increased when self-reported infections in the year before the study visit were combined with study diagnosed infections. Antibodies to HCV were least common in MSM. Antibodies to HSV-2 were least common in heterosexual men. Most MSM, but not heterosexual men or women, agreed that STI testing should be offered every year.

Strengths and weaknesses of study methods
-----------------------------------------

Strengths of this study are that it enrolled a prospective sample of both male and female patients and used standardised methods of data collection and validated laboratory tests in a single centre. The number of patients assessed for eligibility matched the sample size calculation but the precision of STI prevalence estimates was reduced because fewer patients than planned were eligible; nearly a third of patients assessed reported that they had not had sexual intercourse in the previous year. We might have missed STI diagnoses if they were, in fact, sexually active but we think this unlikely, especially since so few STI were diagnosed in the enrolled heterosexual men and women. The number of participants enrolled was comparable to that of HIV-infected patients in other single centre studies ([@ref-2]; [@ref-22]; [@ref-20]) with a participation rate amongst eligible patients of about 50%. To minimise disruption to the clinic during the study period, we did not collect data about those who declined participation so our interpretation assumes that non-participation was not associated with the probability of having an STI diagnosis.

Comparison with other studies
-----------------------------

We did not find any other prospective studies comparing the prevalence of laboratory-detected STI in MSM, heterosexual men and women. Given the role of STI in driving HIV transmission ([@ref-9]), the number of prospective studies examining STI in any groups of HIV-infected people in the era of cART is modest. One global review found 37 studies of any design in any population published from 2000 to 2010 ([@ref-15]). Only seven of these studies examined acute bacterial STI in prospective systematic samples of HIV-infected patients in Europe, Australia or North America ([@ref-29]; [@ref-2]; [@ref-18]; [@ref-22]; [@ref-14]; [@ref-20]; [@ref-10]) and only one included women ([@ref-18]). In MSM in our study the estimated point prevalences of chlamydia (11% any site), LGV (1%), gonorrhoea (3% any site), newly reactive syphilis serology (5%) were consistent with: another study in Switzerland (11% anorectal chlamydia serovars D-K, 1% LGV) ([@ref-10]); Australia (3% rectal or urethral gonorrhoea, 8% rectal or urethral chlamydia) ([@ref-14]); and North America (14% gonorrhoea, chlamydia or newly reactive syphilis serology) ([@ref-20]), (10% gonorrhoea or chlamydia at any site) ([@ref-29]). Other recent studies have estimated a higher prevalence of rectal chlamydia ([@ref-22]). Amongst women, one study in San Francisco found no chlamydia but pharyngeal gonorrhoea in 6% (3/46) women ([@ref-18]). Two studies that included men did not stratify their findings by sexual orientation ([@ref-2]; [@ref-18]).

The cumulative rate of STI in our study, combining new diagnoses and self-reported chlamydia, gonorrhoea and syphilis in the preceding year (28%; 21%--37%) was higher than the combined rates for HIV-negative MSM estimated by [@ref-13]. The prevalence of STI has also been found to be higher in HIV-positive than HIV-negative MSM in Australia ([@ref-14]), Germany ([@ref-11]) and the USA ([@ref-29]). Even if some syphilis infections reported by MSM in our study were old or treated episodes ([@ref-25]), the combined rate in our study was consistent with the findings of a prospective study of 212 MSM in two urban clinics in the USA who were tested at baseline, six and 12 months; 28% (95% CI 22%--34%) tested positive for chlamydia or gonorrhoea at any site or had newly reactive syphilis serology ([@ref-20]). Amongst women, all chlamydia infections were self-reported and the combined prevalence of 4% is compatible with that of sexually active women tested opportunistically in non-HIV clinic settings ([@ref-1]).

Serological evidence of HSV-2 infection was common in all groups in our study and was asymptomatic in most people, as in other studies ([@ref-21]). Hepatitis C was the only infection that was more common in heterosexual men and women than in MSM, even amongst those who reported no recent history of injection drug use. This pattern of seroprevalence has been observed before in the SHCS as a whole ([@ref-19]) and probably reflects infections that resulted from past injection drug use or other parenteral exposures because heterosexual transmission of hepatitis C is uncommon ([@ref-4]). The exponential increase in sexually transmitted hepatitis C infection in MSM in Switzerland ([@ref-27]) began at around the time that we conducted our study. A substantial minority of patients had no serologic immunity against hepatitis B, but we could not differentiate between people who were unvaccinated, had not seroconverted, which is common in people with HIV infection, or in whom titres had waned over time.

Interpretation and implications for STI testing
-----------------------------------------------

The point prevalences of asymptomatic STI in sexually active HIV-infected MSM in our study population were similar to those in countries that recommend regular testing ([@ref-7]; [@ref-12]). STI testing in the routine clinic setting was feasible, most MSM in our study stated that they could discuss sexual health in the HIV outpatient clinic and most would accept regular STI testing. Sampling from the rectum and pharynx of MSM was important because more than half of the chlamydia and gonorrhoea infections were detected at these sites ([@ref-11]). STI prevalences in HIV-infected heterosexual men and women in our study were more similar to those in HIV-uninfected people. Although these patient groups are less willing than MSM to endorse routine STI testing, a sexual health assessment offers opportunities for offering hepatitis B vaccination to non-immune individuals, early treatment for hepatitis C ([@ref-23]) and to find out about the reproductive health needs of HIV-infected women ([@ref-12]).

A major reason for testing and treating STI in HIV-infected people is to reduce the transmissibility of HIV. Diagnosis and treatment of asymptomatic bacterial STI has benefits for the individual if accompanied by information about infections and their prevention for patients and their sexual partners and if partners also receive treatment to prevent re-infection. Specific information for MSM about the risks of STI if they practise serosorting might be required ([@ref-17]). Detecting and treating asymptomatic pharyngeal and rectal gonococcal infections might help to delay the spread of antimicrobial resistance, especially if antimicrobial susceptibility testing allows the prescription of appropriate antibiotic regimens ([@ref-16]). When assessing sexual health in the HIV clinic, patients should be asked specifically about oral and anal sex without condom use so that all potential sites of infection can be sampled.

Population level benefits are less clear. There are no randomised controlled trials of the effects on HIV transmission of diagnosing and treating STI in HIV-positive MSM but a large impact is unlikely because most new HIV infections in MSM are thought to be acquired from people who are unaware that they are HIV-infected ([@ref-26]).

In summary, guidelines about STI testing amongst HIV-infected people should be based on local knowledge about STI prevalence in women and men, and their risk of exposure. Combined prevalence rates of bacterial STI in MSM in our patient population were high and further studies should be done to assess generalizability to, and the need for guidance for, Switzerland as a whole. A regular assessment of sexual health in HIV-infected people, including a sexual history, would allow those at risk of STI to be offered testing, treatment and partner management.
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